【24h】

Thoracic adenoid cystic carcinomas

机译:胸腺样囊性癌

获取原文
获取原文并翻译 | 示例
           

摘要

Adenoid cystic carcinomas in the trachea are rare, but represent around 40% of all tracheal tumours. Other intrathoracic localisations include the carena or proximal airways. Adenoid cystic carcinoma's growth rate is slow so that it is frequently diagnosed at an advanced stage. Pathological identification may be difficult. Treatment in limited tumours is based upon surgical resection often combined to radiotherapy because of close surgical margins. Radiotherapy dose may vary between 45 and 65 Gy according to margins status. Five-year survival rates of 65-80% have been reported after surgery or surgery and postoperative radiotherapy. Among inoperable patients treated with exclusive radiotherapy for tracheal tumours (including adenoid cystic but also squamous cell carcinomas of poorer prognosis), the recommended delivered dose should be over 60 Gy. Five-year survival rate in these very heterogeneous series may vary between 12 and 27%. Local or metastatic recurrences may occur very lately. They are considered chemo-resistant and targeted therapies may prove to be effective in the future.
机译:气管中的腺样囊性癌很少见,但约占所有气管肿瘤的40%。其他胸腔内定位包括肾小管或近端气道。腺样囊性癌的生长速度很慢,因此经常在晚期被诊断出来。病理鉴定可能很困难。有限肿瘤的治疗基于手术切除,由于手术切缘狭窄,通常与放疗结合。放射治疗剂量可能根据切缘状态在45至65 Gy之间变化。据报道,手术后或手术后放疗后的五年生存率为65-80%。在不能接受独家放疗的气管肿瘤(包括腺样囊性癌和预后较差的鳞状细胞癌)无法手术的患者中,推荐的给药剂量应超过60 Gy。在这些非常不同的系列中,五年生存率可能在12%至27%之间变化。局部或转移性复发可能在最近发生。它们被认为是抗化学药品的,靶向疗法可能在将来被证明是有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号